1. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
- Author
-
David J. Curtis, Matthew Greenwood, Andrew Lim, Ian Bilmon, Cameron Curley, Jeff Szer, Marnie Collins, Mark Hertzberg, Duncan Purtill, Glen A Kennedy, Bartlomiej Getta, Ashanka Beligaswatte, Matthew Wright, John Moore, Tasman Armytage, John Gibson, Kate Mason, Chun Yew Fong, David Ritchie, Ian D. Lewis, Katherine Fielding, and Anne Maree Johnston
- Subjects
Oncology ,medicine.medical_specialty ,Myeloid ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Salvage therapy ,Hematopoietic stem cell transplantation ,Donor lymphocyte infusion ,Surgery ,Radiation therapy ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Internal medicine ,Internal Medicine ,medicine ,business ,Survival rate ,030215 immunology - Abstract
BACKGROUND/AIMS: We sought to determine factors associated with the overall survival from relapse (OSR) of acute myeloid leukaemia (AML) after allogeneic haemopoietic stem cell transplantation (alloHSCT) and the effect of first salvage therapy and subsequent graft-versus-host disease (GVHD) on OSR. METHODS: Data on 386 patients from nine Australian centres with relapsed AML post-alloHSCT were collected retrospectively. OSR was calculated using the Kaplan-Meier method. Univariate and multivariate analyses were conducted using the log-rank test and proportional hazards modelling, respectively and a prognostic index for OSR was derived from multivariate modelling. RESULTS: On multivariate analysis, relapse within 6 months (hazard ratio (HR) 2.4, P
- Published
- 2018